Therapeutic cancer vaccines: reasons to believe

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Current immunotherapies like anti-PD1 antibodies and chimeric antigen receptor T cells show partial success in controlling tumors.
• Therapeutic cancer vaccines aim to harness the immune system against tumor-specific or associated antigens, but have faced challenges.
• Emerging data suggests potential effectiveness of cancer vaccines, particularly in combination with checkpoint inhibitors for advanced solid tumors.

Purpose of the Study:

• To evaluate the potential of therapeutic cancer vaccines in controlling tumors.
• To explore whether current successes in cancer immunotherapy can be generalized to vaccine approaches.
• To investigate the critical role of antigen selection in the efficacy of cancer vaccines.

Main Methods:

• Review of existing data on anti-PD1 antibodies, chimeric antigen receptor T cells, and therapeutic cancer vaccines.
• Analysis of emerging clinical trial data for cancer vaccines in advanced solid tumors.
• Consideration of vaccine platform effectiveness and antigen targeting strategies.

Main Results:

• Positive data is emerging for therapeutic cancer vaccines, particularly as combination therapies with checkpoint inhibitors in advanced solid tumors.
• The effectiveness of cancer vaccines may depend significantly on the specific antigens targeted.
• The field is questioning whether the correct antigens are being pursued for vaccine development.

Conclusions:

• Therapeutic cancer vaccines show emerging promise, especially when combined with checkpoint inhibitors for advanced solid tumors.
• Optimizing antigen selection is crucial for improving vaccine efficacy.
• Targeting specific antigens with effective vaccine platforms in patients with low disease burden may offer significant long-term benefits as monotherapy.